Trade: FDA approves Merck's Welireg + Keytruda or Keytruda Qlex?
Resolution criteria on PolyGram: As of market creation, the FDA's expected decision date for the specified application is June 19, 2026. This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants full or conditional approval for Merck's Welireg + Keytruda or Keytruda Qlex as a treatment for adjuvant treatment of clear cell renal cell carcinoma following nephrectomy by July 3, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No." An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental…
PolyGram is an on-chain prediction market where you trade YES or NO outcome shares with real USDC on Polygon. For this market, buy YES if you believe the event will happen, or NO if you think it won't. Your maximum loss is your stake — winning shares pay $1.00 each at resolution. Unlike sportsbooks, there is no house edge: prices are set by supply and demand from other traders and reflect the crowd's real-time probability.
- Liquidity
- $127
- Total Volume
- —
- 24h Volume
- —
- Open Interest
- —
Market outcomes
| FDA approves Merck's Welireg + Keytruda or Keytruda Qlex? | 69% YES | 32% NO |
Market context
Merck is seeking FDA approval for Welireg (belzutifan) combined with Keytruda (pembrolizumab) as adjuvant therapy for clear cell renal cell carcinoma following nephrectomy. The regulatory decision is expected by 19 June 2026, with this market settling on approval status by 3 July 2026. The 69% implied probability on Polymarket's order book reflects moderate confidence in a positive outcome, though meaningful uncertainty remains around the FDA's assessment of the clinical benefit-risk profile.
Merck's combination therapy builds on established efficacy data. Keytruda already holds multiple approvals in renal cell carcinoma, whilst Welireg demonstrated activity in earlier-stage trials. The FDA's recent approvals of other adjuvant immunotherapy combinations in oncology—including CheckMate 914 (nivolumab plus ipilimumab) and KEYNOTE-564 (pembrolizumab monotherapy)—suggest receptiveness to adjuvant approaches in this indication. However, regulatory decisions hinge on comparative efficacy claims and safety tolerability in the adjuvant setting, where patient populations differ from metastatic cohorts.
Key catalysts include any FDA communications regarding review timeline extensions, clinical data presentations at oncology conferences, or manufacturing/compliance questions that could delay the decision beyond the June target. Traders should monitor Merck earnings calls and SEC filings for updates on regulatory interactions. The probability reflects confidence in the underlying data package, but adjuvant approvals occasionally face additional scrutiny around long-term safety and quality-of-life considerations that could shift the outcome closer to the settlement deadline.
Wikipedia Context
-
Food and Drug AdministrationThe Food and Drug Administration (FDA) is a federal agency of the United States Department of Health and Human Services (HHS). The FDA is responsible for protecting and promoting public health through the control and supervision of food safety, tobacco products, caffeine products, dietary supplements, prescription and over-the-counter pharmaceutical drugs (m
How this market resolves
Resolution is handled by the UMA optimistic oracle on Polygon. A proposer submits the outcome, a two-hour dispute window opens, and if no one stakes a counter-claim the payout is final. Contested outcomes escalate to UMA token-holder voting. Payouts clear in USDC to the winning side.
How to trade this market step by step
The mechanics for trading "FDA approves Merck's Welireg + Keytruda or Keytruda Qlex?" are the same as any other PolyGram event contract. Each YES share resolves to $1 if the event happens, or $0 if it doesn't. The current price between 0¢ and 100¢ is the market's probability estimate, set live by the order book.
- Sign in on polygram.ink with your email — no full KYC under $1,500 lifetime trading volume.
- Deposit USDC on Polygon (lowest fees, ~$0.01 per transaction) or Ethereum. Funds credit after 12 confirmations.
- Pick a side. Buy YES if you believe the event will happen; buy NO if you think it won't. The current YES price reflects the market's collective probability.
- Size your position. If you stake 100 USDC at 69% YES, you'll receive shares that pay $145 if YES resolves true — a 45% gross return. If NO resolves, your shares are worth $0.
- Set risk controls (optional). Stop-loss, take-profit, and limit-order types all supported. Use the trade ticket's slippage box to cap your maximum entry price.
- Wait for resolution. When the event resolves on-chain via the UMA optimistic oracle, the winning side settles to 100¢ automatically and USDC hits your balance within seconds. Withdrawable to any wallet you control.
How active is this market?
$0 in lifetime turnover and $127 of resting liquidity puts this market in the below the median by volume for drug contracts on PolyGram. Order-book depth is thin — large orders may need to be split across the book or executed as limit orders.
The market has been open for under a month — fresh enough that information asymmetry remains a real factor.
Higher-volume markets tend to have tighter spreads and faster price discovery — meaning the displayed YES/NO percentages are more likely to reflect the true crowd-implied probability rather than a single trader's directional view.
Key terms
- YES / NO share
- A binary outcome token that pays $1.00 if the underlying claim resolves true (YES) or false (NO), and $0 otherwise. The market price between 0¢ and 100¢ is the implied probability.
- CLOB
- Central limit order book. The matching engine that pairs YES buyers with NO buyers (effectively the same trade). Polymarket's CLOB on Polygon executes trades on-chain via the conditional-tokens framework.
- Liquidity
- USDC capital sitting in resting limit orders inside the order book. Deeper liquidity means smaller slippage on large trades and a tighter bid-ask spread.
- UMA optimistic oracle
- The on-chain dispute system that settles each Polymarket market. A proposer submits the outcome, a two-hour challenge window opens, and unchallenged proposals finalise the resolution.
- Slippage
- The difference between the displayed mid-price and your fill price. Affects market orders most; limit orders avoid slippage but may take time to fill.
- Conditional token
- ERC-1155 outcome share issued by Gnosis Conditional Tokens on Polygon. The token type that resolves to $1.00 or $0.00 at settlement.
Frequently asked questions
What is the current probability for "FDA approves Merck's Welireg + Keytruda or Keytruda Qlex?"?
As of today, traders on Polymarket price this outcome at 69%. The number updates continuously as the order book clears. PolyGram mirrors the same live odds with locale-aware formatting and USDC settlement.
How does this market resolve?
Resolution is handled by the UMA optimistic oracle on Polygon. A proposer submits the outcome, a 2-hour dispute window opens, and if uncontested the payout is final. Contested outcomes escalate to UMA token holders.
When does this market close?
This prediction market is scheduled to close on 19 June 2026. After the resolving event occurs, settlement typically clears within 24 hours once the UMA optimistic oracle confirms the outcome. All payouts are in USDC on the Polygon network.
How can I trade on "FDA approves Merck's Welireg + Keytruda or Keytruda Qlex?"?
To trade on this prediction market, create a free PolyGram account at polygram.ink, deposit USDC via Polygon, and place a YES or NO order on the outcome you believe in. You can learn more on our how-it-works page. Your maximum loss is limited to your stake — there is no leverage or margin.
What happens when the market resolves?
When the outcome is determined, winning YES shares pay out $1.00 each in USDC, while losing shares pay $0. Settlement is handled by the UMA optimistic oracle on Polygon — a proposer submits the result, a two-hour dispute window opens, and if uncontested, payouts are distributed automatically. You can withdraw your winnings to any Polygon wallet.
Risk and regulatory note
Prediction-market positions can lose 100% of staked capital. Outcomes are uncertain by definition — historical accuracy of crowd-implied probabilities is high in aggregate but not for any single market. PolyGram does not provide investment advice. Trade only with capital you can afford to lose.
Regulatory status varies by jurisdiction. Germany, the United States, and most EU countries treat Polymarket-style event contracts under one of three frameworks: financial derivative, gambling product, or unregulated novel asset. Consult local counsel before trading.
Related prediction markets
Explore more prediction market odds and trading opportunities on PolyGram: